Cabozantinib: all 199 studies that test it

Page 1 of 2. Open to participants first (35), then studies with results posted, then the rest; newest registration first within each.

• Fight Osteosarcoma Through European Research Evolving Study Platform From Diagnosis to RelapseRecruitingNCT07871864Phase 3
• Long-Term Extension Study for Participants Previously Enrolled in an Exelixis-Sponsored StudyEnrolling by invitationNCT07620574Phase 3
• Extension Study for Participants in Studies That Include Belzutifan (MK-6482-043/LITESPARK-043)RecruitingNCT07405164Phase 3
• Metastatic Ewing's Trial Testing Schedule Enhancement to Improve OutcomesRecruitingNCT07194044Phase 1
• Modulation of the Bone Immune Microenvironment Following Cabozantinib Treatment of Bone Metastatic Clear Cell Renal Cell Carcinoma: Proof of Concept StudyRecruitingNCT07187869Phase 1
• Cabozantinib for Progressive HCC Post-first-line Immuno-oncologic Combination TherapyNot yet recruitingNCT07151326Phase 2
• Cabozantinib and Nivolumab Among Older Patients With Renal Cell CarcinomaRecruitingNCT06934057Phase 4
• A Study of Abemaciclib and Cabozantinib in People With Clear Cell Renal Cell Carcinoma (ccRCC)RecruitingNCT06835972Phase 1/2
• A Phase 2, Single Arm Study of Cabozantinib in Patients With Hepatocellular Carcinoma Who Have Received Prior Atezolizumab and BevacizumabNot yet recruitingNCT06535737Phase 2
• Study of Cabozantinib With Selumetinib for Plexiform NeurofibromasRecruitingNCT06502171Phase 1
• Efficacy of Organoid-Based Drug Screening to Guide Treatment for Locally Advanced Thyroid CancerRecruitingNCT06482086Phase 2
• Study of Targeted Therapy vs. Chemotherapy in Patients With Thyroid CancerRecruitingNCT06475989Phase 3
• CARE1 Pragmatic Clinical TrialRecruitingNCT06364631Phase 3
• Cabozantinib With Ifosfamide in Relapsed/Refractory SarcomasRecruitingNCT06156410Phase 1
• KO-2806 Monotherapy and Combination Therapies in Advanced Solid TumorsRecruitingNCT06026410Phase 1
• Sequential Treatment of Cabozantinib for Advanced Renal Cell Carcinoma (RCC)RecruitingNCT05931393Phase 2
• A Study of Combining Cabozantinib and Atezolizumab for Advanced/Metastatic NSCLC (Cabatezo-1)Not yet recruitingNCT05859217Phase 2
• Dose-Escalation Study of Cabozantinib in Combination With Lutetium-177 (177Lu)-PSMA-617 in Patients With Metastatic Castration-Resistant Prostate CancerRecruitingNCT05613894Phase 1
• A Pilot Phase II Study of Maintenance Cabozantinib Plus Pembrolizumab for Patients With Metastatic Squamous Non-Small Cell Lung Cancer (sqNSCLC)RecruitingNCT05613413Phase 2
• Cabozantinib for Patients With Recurrent or Progressive MeningiomaRecruitingNCT05425004Phase 2
• Genetic Testing to Select Therapy for the Treatment of Advanced or Metastatic Kidney Cancer, OPTIC RCC StudyRecruitingNCT05361720Phase 2
• Cabo-POLARIS : A Trial to Evaluate Cabozantinib Among Haemodialysied PatientsNot yet recruitingNCT05241561Phase 2
• A Study of Cabozantinib as a Maintenance Agent to Prevent Progression or Recurrence in High-Risk Pediatric Solid TumorsRecruitingNCT05135975Phase 2
• Phase I Study of Tumor Treating Fields (TTF) in Combination With Cabozantinib or With Pembrolizumab and Nab-Paclitaxel in Patients With Advanced Solid Tumors Involving the Abdomen or ThoraxRecruitingNCT05092373Phase 1
• Cabozantinib and Lanreotide as Treatment for Gastroenteropancreatic Neuroendocrine TumorsRecruitingNCT05048901Phase 1/2
• A Phase II Study of Nivolumab With Ipilimumab and Cabozantinib in Patients With Untreated Renal Cell Carcinoma Brain MetastasesRecruitingNCT05048212Phase 2
• Atezolizumab and Cabozantinib for the Treatment of Adolescents and Young Adults With Recurrent or Metastatic Osteosarcoma, TACOS StudyRecruitingNCT05019703Phase 2
• A Trial Evaluating the Activity and Safety of Combination Between Cabozantinib and Temozolomide in Lung and GEP-NENS Progressive After Everolimus, Sunitinib or PRRT (CABOTEM)RecruitingNCT04893785Phase 2
• Cabozantinib Combined With Ipilimumab/Nivolumab and TACE in Patients With Hepatocellular CarcinomaRecruitingNCT04472767Phase 2
• Cabozantinib to Treat Recurrent Liver Cancer Post TransplantRecruitingNCT04204850Phase 2
• A Study Evaluating the Activity of Anti-cancer Treatments Targeting Tumor Molecular Alterations/Characteristics in Advanced / Metastatic Tumors.RecruitingNCT04116541Phase 2
• Immune Checkpoint Therapy vs Target Therapy in Reducing Serum HBsAg Levels in Patients With HBsAg+ Advanced Stage HCCRecruitingNCT03899428Phase 2
• Pan Tumor Rollover StudyRecruitingNCT03899155Phase 2
• The Drug Rediscovery Protocol (DRUP Trial)RecruitingNCT02925234Phase 2
• Cabozantinib in Patients With RET Fusion-Positive Advanced Non-Small Cell Lung Cancer and Those With Other Genotypes: ROS1 or NTRK Fusions or Increased MET or AXL ActivityRecruitingNCT01639508Phase 2
• Study of Ipilimumab, Nivolumab, and Cabozantinib in Patients With Cutaneous MelanomaTerminatedNCT05200143Phase 2Results posted
• Cabozantinib and Pembrolizumab in Metastatic PancreasCompletedNCT05052723Phase 2Results posted
• Atezolizumab + Cabozantinib in Patients w/ Metastatic, Refractory Pancreatic CancerCompletedNCT04820179Phase 2Results posted
• Cabozantinib in Patients With Metastatic Castrate Resistant Prostate Cancer (mCRPC)TerminatedNCT04631744Phase 2Results posted
• Testing the Combination of the Anti-cancer Drugs XL184 (Cabozantinib) and Nivolumab in Patients With Advanced Cancer and HIVActive, not recruitingNCT04514484Phase 1Results posted
• Cabozantinib in Patients With Advanced Hepatocellular Carcinoma With Child Pugh Class B Cirrhosis After First-Line TherapyTerminatedNCT04497038Phase 1/2Results posted
• Study of Atezolizumab in Combination With Cabozantinib Versus Docetaxel in Patients With Metastatic Non-Small Cell Lung Cancer Previously Treated With an Anti-PD-L1/PD-1 Antibody and Platinum-Containing ChemotherapyCompletedNCT04471428Phase 3Results posted
• Study of Cabozantinib in Combination With Atezolizumab Versus Second NHT in Subjects With mCRPCActive, not recruitingNCT04446117Phase 3Results posted
• Trial of Cabozantinib Plus Atezolizumab in Advanced and Progressive Neoplasms of the Endocrine System. The CABATEN StudyCompletedNCT04400474Phase 2Results posted
• Cabozantinib in Patients With Hepatocellular Carcinoma (ACTION)CompletedNCT04316182Phase 2Results posted
• Cabozantinib With Radiation Therapy for the Treatment of Sarcomas of the ExtremitiesTerminatedNCT04220229Phase 1/2Results posted
• Cabozantinib for Advanced or Metastatic Cervical Carcinoma After Platinum Treatment FailureCompletedNCT04205799Phase 2Results posted
• Cabozantinib and Temozolomide for the Treatment of Unresectable or Metastatic Leiomyosarcoma or Other Soft Tissue SarcomaActive, not recruitingNCT04200443Phase 2Results posted
• Cabozantinib and Nivolumab for Carcinoid TumorsCompletedNCT04197310Phase 2Results posted
• Ph II Study of Cabozantinib With Pembrolizumab in Metastatic Gastric and Gastroesophageal AdenocarcinomaCompletedNCT04164979Phase 2Results posted
• Nivolumab/Ipilimumab Plus Cabozantinib in Patients With Unresectable Advanced MelanomaActive, not recruitingNCT04091750Phase 2Results posted
• Testing the Combination of XL184 (Cabozantinib), Nivolumab, and Ipilimumab for Poorly Differentiated Neuroendocrine TumorsActive, not recruitingNCT04079712Phase 2Results posted
• Neoadjuvant Cabozantinib in Treating Patients With Locally Advanced Kidney CancerActive, not recruitingNCT04022343Phase 2Results posted
• Immediate Prostatectomy vs. Cabozantinib Followed by Prostatectomy in Men With High-Risk Prostate CancerTerminatedNCT03964337Phase 2Results posted
• Cabozantinib and Pembrolizumab for Advanced Metastatic MelanomaTerminatedNCT03957551Phase 1/2Results posted
• Study of Cabozantinib as 2nd Line Treatment in Subjects With Locally Advanced or Metastatic Renal Cell Carcinoma (RCC) With a Clear-Cell Component Who Progressed After 1st Line Treatment With Checkpoint InhibitorsCompletedNCT03945773Phase 2Results posted
• Study of Cabozantinib in Combination With Nivolumab and Ipilimumab in Patients With Previously Untreated Advanced or Metastatic Renal Cell CarcinomaActive, not recruitingNCT03937219Phase 3Results posted
• Testing the Combination of Cabozantinib, Nivolumab, and Ipilimumab (CaboNivoIpi) for Advanced Differentiated Thyroid CancerActive, not recruitingNCT03914300Phase 2Results posted
• Study of Cabozantinib in Combination With Atezolizumab Versus Sorafenib in Participants With Advanced Hepatocellular Carcinoma (HCC) Who Have Not Received Previous Systemic Anticancer TherapyActive, not recruitingNCT03755791Phase 3Results posted
• A Study of Cabozantinib Compared With Placebo in Subjects With Radioiodine-refractory Differentiated Thyroid Cancer Who Have Progressed After Prior Vascular Endothelial Growth Factor Receptor (VEGFR) -Targeted TherapyActive, not recruitingNCT03690388Phase 3Results posted
• Adaptive Tyrosine Kinase Inhibitor (TKI) Therapy In Patients With Thyroid CancerTerminatedNCT03630120Phase 2Results posted
• A Phase 2 Study of Cabozantinib in Japanese Participants With Advanced Hepatocellular CarcinomaCompletedNCT03586973Phase 2Results posted
• Investigating Cabozantinib in Patients With Refractory Metastatic Colorectal CancerCompletedNCT03542877Phase 2Results posted
• Cabozantinib Plus Pembrolizumab as First-Line Therapy for Cisplatin-Ineligible Advanced Urothelial CarcinomaCompletedNCT03534804Phase 2Results posted
• Nivolumab, Cabozantinib S-Malate, and Ipilimumab in Treating Patients With Recurrent Stage IV Non-small Cell Lung CancerCompletedNCT03468985Phase 2Results posted
• Pembrolizumab & Cabozantinib in Patients With Head and Neck Squamous Cell CancerActive, not recruitingNCT03468218Phase 2Results posted
• Testing Cabozantinib in Patients With Advanced Pancreatic Neuroendocrine and Carcinoid TumorsActive, not recruitingNCT03375320Phase 3Results posted
• Cabozantinib in Treating Patients With Locally Advanced or Metastatic Unresectable Adrenocortical CarcinomaCompletedNCT03370718Phase 2Results posted
• A Phase 2 Study of Cabozantinib in Japanese Participants With Advanced Renal Cell CarcinomaCompletedNCT03339219Phase 2Results posted
• A Phase II Study of Nivolumab in Combination With Cabozantinib for Metastatic Triple-negative Breast CancerCompletedNCT03316586Phase 2Results posted
• Cabozantinib and Erlotinib for Patients With EGFR and c-Met Co-expressing Metastatic Pancreatic AdenocarcinomaTerminatedNCT03213626Phase 2Results posted
• Cabozantinib as a Targeted Strategy to Reverse Carfilzomib Resistance in Refractory Multiple MyelomaTerminatedNCT03201250Phase 1/2Results posted
• Study of Pembrolizumab and Cabozantinib in Patients With Metastatic Renal Cell CarcinomaCompletedNCT03149822Phase 1/2Results posted
• A Study of Nivolumab Combined With Cabozantinib Compared to Sunitinib in Previously Untreated Advanced or Metastatic Renal Cell CarcinomaCompletedNCT03141177Phase 3Results posted
• Pilot Study of Cabozantinib for Recurrent or Progressive Central Nervous System Tumors in ChildrenTerminatedNCT02885324Phase 2Results posted
• Cabozantinib-S-Malate in Treating Younger Patients With Recurrent, Refractory, or Newly Diagnosed Sarcomas, Wilms Tumor, or Other Rare TumorsActive, not recruitingNCT02867592Phase 2Results posted
• Study Assessing Activity of Molecularly Matched Targeted Therapies in Select Tumor Types Based on Genomic AlterationsCompletedNCT02795156Phase 2Results posted
• Testing Cabozantinib, Crizotinib, Savolitinib and Sunitinib in Kidney Cancer Which Has ProgressedCompletedNCT02761057Phase 2Results posted
• Cabozantinib-S-Malate in Treating Patients With Recurrent or Progressive Ovarian, Fallopian Tube, or Primary Peritoneal CancerCompletedNCT02315430Phase 2Results posted
• Cabozantinib S-malate in Treating Patients With Metastatic Pheochromocytomas or Paragangliomas That Cannot Be Removed by SurgeryCompletedNCT02302833Phase 2Results posted
• Cabozantinib S-malate in Treating Patients With Relapsed Osteosarcoma or Ewing SarcomaActive, not recruitingNCT02243605Phase 2Results posted
• Trial of Cabozantinib (XL184) in Non-Small Cell Lung Cancer With Brain MetastasesTerminatedNCT02132598Phase 2Results posted
• Cabozantinib for Plexiform Neurofibromas (PN) in Subjects With NF1 in Children and AdultsCompletedNCT02101736Phase 2Results posted
• Cabozantinib in Recurrent/Metastatic Merkel Cell CarcinomaTerminatedNCT02036476Phase 2Results posted
• Combo of Cabozantinib With Abiraterone in Chemotherapy-Naïve Subjects With Bone-Metastatic CRPCTerminatedNCT01995058Phase 2Results posted
• Cabozantinib (XL-184) Monotherapy for Advanced CholangiocarcinomaCompletedNCT01954745Phase 2Results posted
• Cabozantinib S-Malate in Treating Patients With Recurrent or Metastatic Endometrial CancerCompletedNCT01935934Phase 2Results posted
• Study of Cabozantinib (XL184) vs Placebo in Subjects With Hepatocellular Carcinoma Who Have Received Prior SorafenibCompletedNCT01908426Phase 3Results posted
• A Study of Two Different Doses of Cabozantinib (XL184) in Progressive, Metastatic Medullary Thyroid CancerActive, not recruitingNCT01896479Phase 4Results posted
• Cabozantinib-S-Malate and Erlotinib Hydrochloride in Treating Patients With Previously Treated Metastatic Non-Small Cell Lung CancerCompletedNCT01866410Phase 2Results posted
• Cabozantinib (XL184) in Patients With Relapsed or Refractory MyelomaCompletedNCT01866293Phase 1/2Results posted
• A Study of Cabozantinib (XL184) vs Everolimus in Subjects With Metastatic Renal Cell CarcinomaCompletedNCT01865747Phase 3Results posted
• Cabozantinib-s-malate or Sunitinib Malate in Treating Patients With Previously Untreated Locally Advanced or Metastatic Kidney CancerCompletedNCT01835158Phase 2Results posted
• Cabozantinib-S-Malate Compared With Temozolomide or Dacarbazine in Treating Patients With Metastatic Melanoma of the Eye That Cannot Be Removed by SurgeryCompletedNCT01835145Phase 2Results posted
• A Phase II Study of Cabozantinib (XL184) Therapy in Castrate Resistant Prostate Cancer (CRPC) With Visceral MetastasesCompletedNCT01834651Phase 2Results posted
• Cabozantinib S-Malate in Treating Patients With Advanced Solid Tumors and Human Immunodeficiency VirusCompletedNCT01822522Phase 1Results posted
• Cabozantinib-S-Malate in Treating Patients With Hormone-Resistant Metastatic Prostate CancerCompletedNCT01812668Not applicableResults posted
• Cabozantinib-S-Malate in Treating Patients With Refractory Thyroid CancerCompletedNCT01811212Phase 2Results posted
• Cabozantinib for Adults With Advanced Soft Tissue SarcomaCompletedNCT01755195Phase 2Results posted
• Cabozantinib for Metastatic Triple Negative BrCaCompletedNCT01738438Phase 2Results posted

← Cabozantinib overview